Trial · NCT05054478
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | VGPR or better at the completion of induction phase | completion of induction phase [4 Months] | The VGPR or better rate (as determined by the reviewer) is defined as the proportion of patients with confirmed IMWG criteria for VGPR, CR or stringent CRrelative to the total number of patients in the ITT population |
| Secondary | Progression Free Survival | 3 years | |
| Secondary | Response rates (sCR, CR, VGPR, PR, SD): | after induction [4 months] | |
| Secondary | Response rates (sCR, CR, VGPR, PR, SD): | after ASCT n°2 [10 months] | |
| Secondary | Response rates (sCR, CR, VGPR, PR, SD): | after second consolidation phase [22 months] | |
| Secondary | Response rates (sCR, CR, VGPR, PR, SD): | end of treatment [34 months] | |
| Secondary | Overall response rate (ORR) | after induction [4 months] | |
| Secondary | Overall response rate (ORR) | after ASCT n°2 [10 months] | |
| Secondary | Overall response rate (ORR) | after second consolidation phase [22 months] | |
| Secondary | Overall response rate (ORR) | end of treatment [34 months] | |
| Secondary | Overall survival (OS) | 3 years | |
| Secondary | Time to progression (TTP) | 3 years | |
| Secondary | Duration of response (DOR) | 3 years | |
| Secondary | Safety | Whole trial duration [48 months] | Adverse Events |
| Secondary | MRD negative rate assessed by NGS | End of induction [4 months] | |
| Secondary | MRD negative rate assessed by NGS | after ASCT n°2 [10 months] | |
| Secondary | MRD negative rate assessed by NGS | after second consolidation phase [22 months] | |
| Secondary | MRD negative rate assessed by NGS | end of treatment [34 months] | |
| Secondary | Quality of life | End of induction [4 months] | defined using EORTC QLQ-C30 domain scores |
| Secondary | Quality of life | after ASCT n°2 [10 months] | defined using EORTC QLQ-C30 domain scores |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05054478/registered